香雪制药(300147) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥613,719,586.39, representing a decrease of 22.41% compared to the same period last year[3] - The net profit attributable to shareholders was a loss of ¥54,380,193.73, a decline of 320.85% year-over-year[3] - The net cash flow from operating activities was negative at ¥14,969,306.51, down 131.19% from the previous year[3] - The company reported a basic earnings per share of -¥0.082, a decrease of 305.00% compared to the previous year[3] - Total operating revenue for the current period is $613.72 million, a decrease of 22.4% compared to $790.93 million in the previous period[23] - Operating profit turned negative at -$41.30 million, compared to a profit of $37.23 million in the previous period[24] - Net profit for the current period is -$41.90 million, a significant decline from a profit of $32.23 million in the previous period[24] - Basic and diluted earnings per share are both -$0.082, down from $0.040 in the previous period[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,170,462,439.30, a decrease of 1.85% from the end of the previous year[4] - As of March 31, 2022, the company's total assets amounted to 11.17 billion CNY, a decrease from 11.38 billion CNY at the beginning of the year[20] - The company's total liabilities decreased to approximately 7.45 billion CNY from 7.62 billion CNY, a reduction of about 2.2%[21] - The company's cash and cash equivalents increased to approximately 356.83 million CNY from 196.12 million CNY at the beginning of the year, representing an increase of about 81.9%[19] - Accounts receivable rose to approximately 1.16 billion CNY from 1.10 billion CNY, reflecting an increase of about 6%[19] - The company reported a decrease in inventory from approximately 761.46 million CNY to 709.49 million CNY, a decline of about 6.8%[19] Investment and Financing Activities - The company received government subsidies amounting to ¥5,900,042.62 during the reporting period[6] - The investment income increased by 2454.75% due to the sale of a subsidiary, Guangzhou Xiangxue Asia Beverage Co., Ltd.[8] - Cash flow from investing activities generated a net inflow of $282.87 million, a turnaround from a net outflow of -$142.31 million in the previous period[29] - Cash flow from financing activities resulted in a net outflow of -$111.11 million, slightly improved from -$123.26 million in the previous period[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 57,935[10] - The company approved the repurchase and cancellation of 82,390 restricted shares at a price of 3.274 CNY per share, reducing total share capital from 661,361,435 shares to 661,279,045 shares[15] - The total number of restricted shares at the beginning of the period was 4,763,909, with no shares released or added during the reporting period[13] Corporate Actions and Developments - The company completed a capital increase of RMB 100 million for its wholly-owned subsidiary, raising its registered capital from RMB 160 million to RMB 260 million[14] - The company transferred 63% equity of its subsidiary, Guangzhou Xiangxue Asia Beverage Co., Ltd., for a total of RMB 81.9 million, with all transfer procedures completed by the end of the reporting period[14] - The company agreed to transfer a fund share of 50 million CNY from Guangzhou Huacheng Venture Capital Partnership to Jiadu Group for 56.44 million CNY, and an 18% stake in Guangzhou Huacheng Venture Capital Management for 9.52 million CNY[15] - The company decided to terminate the preparation for establishing Huacheng Life Insurance Co., Ltd., with a planned investment of 160 million CNY for a 16% stake due to macroeconomic and financial policy changes[16] - The subsidiary, Xiangxue Life Science Technology, received approval for clinical trials of the new drug TAEST1901, aimed at treating advanced liver cancer and other late-stage tumors[16] Audit and Reporting - The first quarter report has not been audited[30] - The report was presented by the Chairman, Wang Yonghui, on April 28, 2022[31]